Stay at the RNA frontier with Hongene — Cutting edge science, technology breakthroughs, and industry insights.
Built to Scale, Chemoenzymatic Ligation Takes RNA Therapeutics from Lab to Clinic
Developing new RNA therapeutics requires years of dedicated effort. However, taking a program from the promise of preclinical models into the reality of clinical development presents the fundamental challenge of scale. Innovators must find a way to manufacture their drug, scaling up from grams to kilograms or even tons, all while maintaining quality, consistency and […]
The Hidden Costs of Fragmented Supply Chains in Nucleic Acid Therapeutics
The rise of nucleic acid therapeutics (NATs) — including oligonucleotides such as siRNA, mRNA-based products, and CRISPR-based drugs — is transforming modern medicine. These precise and potent modalities are advancing rapidly through development, posing new challenges for achieving scalable and compliant manufacturing. Early-stage NAT developers often rely on multiple specialized vendors across different production […]
Chemoenzymatic Synthesis of siRNA and sgRNA Using Ligation Technology
This article explores the limitations of SPOS, and provides an overview of chemoenzymatic ligation, its mechanism, and comparative advantages in siRNA and sgRNA synthesis.
Nov 21, 2025David Butler, CTO
Developing new RNA therapeutics requires years of dedicated effort. However, taking a program from the promise of preclinical models into the reality of clinical development presents the fundamental challenge of scale. Innovators must find a way to manufacture their drug, scaling up from grams to kilograms or even tons, all while maintaining quality, consistency and […]
Oct 1, 2025David Butler, CTO
The rise of nucleic acid therapeutics (NATs) — including oligonucleotides such as siRNA, mRNA-based products, and CRISPR-based drugs — is transforming modern medicine. These precise and potent modalities are advancing rapidly through development, posing new challenges for achieving scalable and compliant manufacturing. Early-stage NAT developers often rely on multiple specialized vendors across different production […]
Mar 18, 2025David Butler, CTO
This article explores the limitations of SPOS, and provides an overview of chemoenzymatic ligation, its mechanism, and comparative advantages in siRNA and sgRNA synthesis.
